Duchenne Muscular Dystrophy Therapeutics and Forecast Market
1 Introduction to Research & Analysis Reports
1.1 Duchenne Muscular Dystrophy Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Duchenne Muscular Dystrophy Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Duchenne Muscular Dystrophy Therapeutics Overall Market Size
2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size: 2023 VS 2030
2.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Duchenne Muscular Dystrophy Therapeutics Players in Global Market
3.2 Top Global Duchenne Muscular Dystrophy Therapeutics Companies Ranked by Revenue
3.3 Global Duchenne Muscular Dystrophy Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Duchenne Muscular Dystrophy Therapeutics Companies in Global Market, by Revenue in 2023
3.5 Global Companies Duchenne Muscular Dystrophy Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Duchenne Muscular Dystrophy Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Duchenne Muscular Dystrophy Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Duchenne Muscular Dystrophy Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Duchenne Muscular Dystrophy Therapeutics Market Size Markets, 2023 & 2030
4.1.2 Pain Management Drugs
4.1.3 Corticosteroids
4.1.4 Prednisolone
4.1.5 Prednisone
4.1.6 Deflazacort
4.2 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2019-2024
4.2.2 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2025-2030
4.2.3 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Duchenne Muscular Dystrophy Therapeutics Market Size, 2023 & 2030
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Home Care
5.2 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2019-2024
5.2.2 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2025-2030
5.2.3 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Duchenne Muscular Dystrophy Therapeutics Market Size, 2023 & 2030
6.2 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2019-2024
6.2.2 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2025-2030
6.2.3 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Duchenne Muscular Dystrophy Therapeutics Revenue, 2019-2030
6.3.2 US Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.3.3 Canada Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.3.4 Mexico Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Duchenne Muscular Dystrophy Therapeutics Revenue, 2019-2030
6.4.2 Germany Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.4.3 France Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.4.4 U.K. Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.4.5 Italy Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.4.6 Russia Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.4.7 Nordic Countries Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.4.8 Benelux Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Duchenne Muscular Dystrophy Therapeutics Revenue, 2019-2030
6.5.2 China Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.5.3 Japan Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.5.4 South Korea Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.5.5 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.5.6 India Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Duchenne Muscular Dystrophy Therapeutics Revenue, 2019-2030
6.6.2 Brazil Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.6.3 Argentina Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue, 2019-2030
6.7.2 Turkey Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.7.3 Israel Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.7.4 Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
6.7.5 UAE Duchenne Muscular Dystrophy Therapeutics Market Size, 2019-2030
7 Duchenne Muscular Dystrophy Therapeutics Companies Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Company Summary
7.1.2 Bristol-Myers Squibb Business Overview
7.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.1.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2019-2024)
7.1.5 Bristol-Myers Squibb Key News & Latest Developments
7.2 FibroGen (US)
7.2.1 FibroGen (US) Company Summary
7.2.2 FibroGen (US) Business Overview
7.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.2.4 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2019-2024)
7.2.5 FibroGen (US) Key News & Latest Developments
7.3 Italfarmaco (Italy)
7.3.1 Italfarmaco (Italy) Company Summary
7.3.2 Italfarmaco (Italy) Business Overview
7.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.3.4 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2019-2024)
7.3.5 Italfarmaco (Italy) Key News & Latest Developments
7.4 Marathon
7.4.1 Marathon Company Summary
7.4.2 Marathon Business Overview
7.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.4.4 Marathon Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2019-2024)
7.4.5 Marathon Key News & Latest Developments
7.5 NS Pharma (US)
7.5.1 NS Pharma (US) Company Summary
7.5.2 NS Pharma (US) Business Overview
7.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.5.4 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2019-2024)
7.5.5 NS Pharma (US) Key News & Latest Developments
7.6 PTC Therapeutics (US)
7.6.1 PTC Therapeutics (US) Company Summary
7.6.2 PTC Therapeutics (US) Business Overview
7.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.6.4 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2019-2024)
7.6.5 PTC Therapeutics (US) Key News & Latest Developments
7.7 Pfizer
7.7.1 Pfizer Company Summary
7.7.2 Pfizer Business Overview
7.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.7.4 Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2019-2024)
7.7.5 Pfizer Key News & Latest Developments
7.8 ReveraGen BioPharma (US)
7.8.1 ReveraGen BioPharma (US) Company Summary
7.8.2 ReveraGen BioPharma (US) Business Overview
7.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.8.4 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2019-2024)
7.8.5 ReveraGen BioPharma (US) Key News & Latest Developments
7.9 Santhera Pharmaceuticals (Switzerland)
7.9.1 Santhera Pharmaceuticals (Switzerland) Company Summary
7.9.2 Santhera Pharmaceuticals (Switzerland) Business Overview
7.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.9.4 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2019-2024)
7.9.5 Santhera Pharmaceuticals (Switzerland) Key News & Latest Developments
7.10 Sarepta Therapeutics (US)
7.10.1 Sarepta Therapeutics (US) Company Summary
7.10.2 Sarepta Therapeutics (US) Business Overview
7.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
7.10.4 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2019-2024)
7.10.5 Sarepta Therapeutics (US) Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Duchenne Muscular Dystrophy Therapeutics Market Opportunities & Trends in Global Market
Table 2. Duchenne Muscular Dystrophy Therapeutics Market Drivers in Global Market
Table 3. Duchenne Muscular Dystrophy Therapeutics Market Restraints in Global Market
Table 4. Key Players of Duchenne Muscular Dystrophy Therapeutics in Global Market
Table 5. Top Duchenne Muscular Dystrophy Therapeutics Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Companies, 2019-2024
Table 8. Global Companies Duchenne Muscular Dystrophy Therapeutics Product Type
Table 9. List of Global Tier 1 Duchenne Muscular Dystrophy Therapeutics Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Duchenne Muscular Dystrophy Therapeutics Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Duchenne Muscular Dystrophy Therapeutics Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Duchenne Muscular Dystrophy Therapeutics Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Duchenne Muscular Dystrophy Therapeutics Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Duchenne Muscular Dystrophy Therapeutics Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2025-2030
Table 30. Bristol-Myers Squibb Company Summary
Table 31. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 32. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 33. Bristol-Myers Squibb Key News & Latest Developments
Table 34. FibroGen (US) Company Summary
Table 35. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 36. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 37. FibroGen (US) Key News & Latest Developments
Table 38. Italfarmaco (Italy) Company Summary
Table 39. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 40. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 41. Italfarmaco (Italy) Key News & Latest Developments
Table 42. Marathon Company Summary
Table 43. Marathon Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 44. Marathon Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 45. Marathon Key News & Latest Developments
Table 46. NS Pharma (US) Company Summary
Table 47. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 48. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 49. NS Pharma (US) Key News & Latest Developments
Table 50. PTC Therapeutics (US) Company Summary
Table 51. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 52. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 53. PTC Therapeutics (US) Key News & Latest Developments
Table 54. Pfizer Company Summary
Table 55. Pfizer Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 56. Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 57. Pfizer Key News & Latest Developments
Table 58. ReveraGen BioPharma (US) Company Summary
Table 59. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 60. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 61. ReveraGen BioPharma (US) Key News & Latest Developments
Table 62. Santhera Pharmaceuticals (Switzerland) Company Summary
Table 63. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 64. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 65. Santhera Pharmaceuticals (Switzerland) Key News & Latest Developments
Table 66. Sarepta Therapeutics (US) Company Summary
Table 67. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings
Table 68. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$, Mn) & (2019-2024)
Table 69. Sarepta Therapeutics (US) Key News & Latest Developments
List of Figures
Figure 1. Duchenne Muscular Dystrophy Therapeutics Segment by Type in 2023
Figure 2. Duchenne Muscular Dystrophy Therapeutics Segment by Application in 2023
Figure 3. Global Duchenne Muscular Dystrophy Therapeutics Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Duchenne Muscular Dystrophy Therapeutics Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Duchenne Muscular Dystrophy Therapeutics Revenue in 2023
Figure 8. By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2019-2030
Figure 9. By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2019-2030
Figure 10. By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2019-2030
Figure 12. By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2019-2030
Figure 14. By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2019-2030
Figure 15. By Country - North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2019-2030
Figure 16. US Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2019-2030
Figure 20. Germany Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 21. France Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2019-2030
Figure 28. China Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 32. India Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2019-2030
Figure 34. Brazil Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2019-2030
Figure 37. Turkey Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Duchenne Muscular Dystrophy Therapeutics Revenue, (US$, Mn), 2019-2030
Figure 41. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Marathon Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Industry Market Size
